Of note, GO seems to be an exemption, as activating signaling mutations, including mutations in NRAS and KRAS in favorable and intermediate ELN 2017 risk AML, are associated with better EFS, most probably explained by increased expression of CD33 on AML blasts [132]. The gene discussed is KRAS; the disease is acute myeloid leukemia.